Join 89bio for a virtual KOL event featuring expert hepatologist Arun J. Sanyal, MD (Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University) who will discuss the unmet need and current treatment landscape for advanced metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis and compensated cirrhosis.

Agenda topics include:

• Non-cirrhotic (F2-F3) advanced MASH: current treatment goals in the evolving landscape and opportunity for therapies in the FGF21 class
• Compensated cirrhosis (F4): unmet medical needs and the importance of anti-fibrotic agents in this patient population
• ENLIGHTEN-Cirrhosis: trial design overview and next steps
• Pegozafermin’s broad commercial opportunity

Pegozafermin is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21) being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is being studied in the Phase 3 ENLIGHTEN trial program for MASH, which builds on the positive ENLIVEN Phase 2b results, and the Phase 3 ENTRUST trial for SHTG.

A live question and answer session will follow the formal presentations.